In the preclinical settings evaluated here, we found the overall tumor behavior for all mice treated with either CD19.4–1BB CAR-T cells or CD19.CD28 CAR-T cells to be indeed statistically different (Figure 2b–f). The gene discussed is CD19; the disease is neoplasm.